SCHEMBL7712829

SCHEMBL7712829

COC(=O)Cc1ccc2c(c1)CCCN2CC(C)N(C[C@H](O[Si](C)(C)C(C)(C)C)c1cccc(Cl)c1)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 7/20 0.36
HDAC6 Q9UBN7 7/20 0.36
HDAC8 Q9BY41 4/20 0.36
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
HDAC10 Q969S8 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
IDO1 P14902 4/20 0.33
KCNH2 Q12809 4/20 0.33
CYP2C19 P33261 1/20 0.33
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7712843 0.96 CTSS (0.32) HDAC1HDAC6HDAC8HDAC3HDAC4
SCHEMBL7708894 0.80 ADRB2 (0.32) ADRB2ADRB1ADRB3
SCHEMBL7716899 0.79 ADRB2 (0.33) ADRB2ADRB1ADRB3
SCHEMBL7714670 0.75 ADRB2 (0.33) ALDH1A1MAPTSMN1; SMN2ADRB2ADRB1
SCHEMBL7716950 0.74 ADRB2 (0.32) ADRB2ADRB1ADRB3
SCHEMBL7714622 0.73
SCHEMBL7712721 0.73 RPS6KB1 (0.30)
SCHEMBL7714532 0.73 ADRB2 (0.32) CYP2C19MAPTADRB2ADRB1ADRB3
SCHEMBL9267480 0.73 AOC3 (0.36) IDO1
SCHEMBL7714803 0.73 PDCD1 (0.33) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0865421-B1 ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS GLAXO GROUP LTD (GB) 2002-03-27 EP disclosed
US-6048872-A DIETETICS; ANTIDIABETIC AGENTS; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS GLAXO WELLCOME INC. (US) 2000-04-11 US disclosed